Skip to main content
. 2022 Jun 24;12:879810. doi: 10.3389/fonc.2022.879810

Table 1.

Relationship between ABAT expression and clinical characteristics.

Clinical characteristics Levels Low expression High expression P
N (%) N (%)
Age <=60 101 (27.1%) 76 (20.4%) 0.011
>60 85 (22.8%) 111 (29.8%)
Gender Female 63 (16.8%) 58 (15.5%) 0.658
Male 124 (33.2%) 129 (34.5%)
T stage T1 79 (21.3%) 104 (28%) 0.013
T2 49 (13.2%) 46 (12.4%)
T3 52 (14%) 28 (7.5%)
T4 6 (1.6%) 7 (1.9%)
N stage N0 135 (52.3%) 119 (46.1%) 0.626
N1 3 (1.2%) 1 (0.4%)
M stage M0 143 (52.6%) 125 (46%) 0.626
M1 3 (1.1%) 1 (0.4%)
Pathologic stage Stage I 76 (21.7%) 97 (27.7%) 0.014
Stage II 44 (12.6%) 43 (12.3%)
Stage III 55 (15.7%) 30 (8.6%)
Stage IV 3 (0.9%) 2 (0.6%)
Histologic grade G1 19 (5.1%) 36 (9.8%) < 0.001
G2 78 (21.1%) 100 (27.1%)
G3 80 (21.7%) 44 (11.9%)
G4 8 (2.2%) 4 (1.1%)
AFP (ng/ml) <=400 86 (30.7%) 129 (46.1%) < 0.001
>400 51 (18.2%) 14 (5%)
Child-Pugh grade A 107 (44.4%) 112 (46.5%) 0.909
B 11 (4.6%) 10 (4.1%)
C 0 (0%) 1 (0.4%)
Vascular invasion No 97 (30.5%) 111 (34.9%) 0.360
Yes 58 (18.2%) 52 (16.4%)